CORRECTION article

Front. Oncol., 10 February 2022

Sec. Pharmacology of Anti-Cancer Drugs

Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.859596

Corrigendum: Suspected Adverse Drug Reactions in Pediatric Cancer Patients in China: An Analysis of Henan Province Spontaneous Reporting System Database

  • 1. School of Medicine and Health Management, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

  • 2. Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

  • 3. Medical Products Administration and Center for Adverse Drug Reaction (ADR) Monitoring of Henan, Zhengzhou, China

  • 4. College of Public Administration, Huazhong University of Science and Technology, Wuhan, China

  • 5. School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

There is an error in the Funding statement. The correct number for the National Youth Natural Science Foundation of China is 71804052.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

pharmacovigilance, drug monitoring, adverse drug reaction reporting systems, pediatric, medical oncology

Citation

Jiao Z, Feng Z, Yan Z, Zhang J, Li G, Wang G, Wang Q and Feng D (2022) Corrigendum: Suspected Adverse Drug Reactions in Pediatric Cancer Patients in China: An Analysis of Henan Province Spontaneous Reporting System Database. Front. Oncol. 12:859596. doi: 10.3389/fonc.2022.859596

Received

21 January 2022

Accepted

24 January 2022

Published

10 February 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

12 - 2022

Updates

Copyright

*Correspondence: Da Feng,

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics